Apremilast: A step forward in the treatment of psoriasis?

The Lancet

Volumn 380, Issue 9843, 2012, Pages 708-709

  Van De Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLIC AMP; CYCLOSPORIN A; DITHRANOL; FUMARIC ACID DERIVATIVE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 23; METHOTREXATE; PHOSPHODIESTERASE IV; PLACEBO; RETINOID; TAR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; COMORBIDITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSPEPSIA; EARLY INTERVENTION; EVIDENCE BASED PRACTICE; GASTROENTERITIS; HEADACHE; HUMAN; KERATINOCYTE; LONG TERM CARE; MONOCYTE; NAUSEA; NEUTROPHIL; NOTE; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RHINOPHARYNGITIS; STIGMA; SYSTEMIC THERAPY; UPPER RESPIRATORY TRACT INFECTION;

EID: 84865383090     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60896-4     Document Type: Note

References (12)

1. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 37: 263-71.
2. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (suppl 2): 1-70.
3. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-96.
4. Böhm D, Stock Gissendanner S, Bangemann K, et al. Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. J Eur Acad Dermatol Venereol 2012; published online Feb 14. DOI:1468-3083.2012.04451.x.
5. Griffiths CE, Gaitanis G, van de Kerkhof P. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol 2006; 20: 921-25.
6. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-88.
7. Van Lümig PP, Driessen RJ, Berends MA, et al. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol 2012; 26: 283-91.
8. Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010; 163: 807-16.
9. Leavy O. Therapeutic targeting of IL-17 for psoriasis. Nat Rev Immunol 2012; 12: 322.
10. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-89.
11. Schafer P, Parton P, Gandhi A, et al. Apremilast, a cyclic AMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159: 842-55.
12. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; published online June 29. http://dx.doi.org/10.1016/S0140-6736(12)60642- 4.